Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 4Neoplasm Metastasis 4Urogenital Neoplasms 2Prostatic Neoplasms 2Lung Neoplasms 2Solitary Fibrous Tumors 1Solid Tumors Harboring NTRK Fusion 1Small Cell Lung Carcinoma 1Sarcoma 1Respiratory Syncytial Virus Infections 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroblastoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Kidney Neoplasms 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1Genital Neoplasms, Male 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

selitrectinib 2larotrectinib 2Suspensions 1Solutions 1Receptor Protein-Tyrosine Kinases 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors Harboring NTRK Fusion × Suspensions × Clear all
NCT04771390 2021-08-25

Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants

Bayer

Phase 1 Completed
52 enrolled
Other solid neoplasm

Solid Tumors Harboring NTRK Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡